ALVOALVOHealthcare · Drug Manufacturers - Specialty & Generic

ALVO Stock Forecast: Alvotech Price Predictions for 2026-2027

Last close, 18 Nov 2026
$4.55
+4.12% on the day

The 7 Wall Street analysts covering Alvotech hold a median 12-month price target of $8 — +75.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 17 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.6B
Ticker Nerd rank
32/ 100
Median analyst target
$8.00
Analysts covering
7
Revenue$105.8M−38.9% y/y
Operating income−$11.7M
Net income−$66.8M
Free cash flow−$64.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.5%
1M
−9.0%
YTD
−11.3%
1Y
−11.0%
From 52W high
−26.0%
From 52W low
+51.7%
$3.00
$6.15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALVO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alvotech on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
32/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
94
Value
88
Volatility
61
Revisions
38
Size
37
Momentum
35
Growth
28
Accruals
21
Issuance
9

Quality (94): The business earns solid, repeatable profits on what it owns.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ALVO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALVO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$3.00$4.00$5.00$6.00$7.00$8.00$9.00Jan 26Apr 26Jul 26Oct 26ALVOHigh $9.00Median $8.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $4.00Median $8.00High $9.00

The green dot is the last close — the median target sits +75.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
10 Nov 2026JefferiesInitiatesBuy$9.00
16 Sept 2026BarclaysUpgradeOverweight$4.00 → $8.00
16 Sept 2026BarclaysUpgradeOverweight—
24 Aug 2026B of A SecuritiesInitiatesBuy$7.00
24 Aug 2026B of A SecuritiesInitiatesBuy—
14 Aug 2026Evercore ISI GroupInitiatesOutperform—
14 Aug 2026Evercore ISI GroupInitiatesOutperform—
24 Mar 2026BarclaysMaintainsUnderweight—
24 Mar 2026BarclaysMaintainsUnderweight$5.00 → $4.00
24 Mar 2026UBSMaintainsBuy—
24 Mar 2026UBSMaintainsBuy$10 → $6.00
9 Dec 2025BarclaysInitiatesUnderweight—
18 Nov 2025UBSMaintainsBuy—
4 Nov 2025Deutsche BankDowngradeHold—
14 Oct 2025Morgan StanleyUpgradeOverweight—
23 Sept 2025Deutsche BankUpgradeBuy—
18 July 2025UBSMaintainsBuy—
14 Feb 2025UBSInitiatesBuy—
25 July 2024BarclaysMaintainsOverweight—
24 May 2024BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ALVO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ALVO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Alvotech returned −11.0% against +12.2% for the S&P 500, dividends included.

ALVO vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26ALVOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALVO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−367.0%
Analysts raising
0
Analysts cutting
1
Fundamentals

Alvotech (ALVO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
42.4×

Cheaper than 17% of US stocks

Price / sales
3.1×

Cheaper than 37% of US stocks

Price / book
−5.9×

Cheaper than 97% of US stocks

EV / EBITDA
33.8×

Cheaper than 7% of US stocks

Growth & margins
Revenue growth (YoY)
−2.0%

Higher than 25% of US stocks

Earnings growth (YoY)
−38.9%

Higher than 14% of US stocks

Gross margin
50.7%

Higher than 63% of US stocks

Operating margin
12.9%

Higher than 71% of US stocks

Net margin
−50.6%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−9.8%

Higher than 36% of US stocks

Return on assets
2.6%

Higher than 62% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Alvotech (ALVO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alvotech has a market value of $1.6B and an enterprise value of $3.0B.

  • Revenue in the twelve months to 30 June 2026: $492.0M. The latest quarter shrank 2.0% year on year.

  • Net income over the same four quarters: −$179.6M, a −36.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$333.8M.

  • Shares outstanding: 356.8M.

  • Trailing P/E: 42.4×; forward P/E: 20.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Alvotech employs 1,279 people — $385K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

ALVO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ALVOAlvotech$1.6B32
ANIPANI Pharmaceuticals, Inc.$1.6B98
PCRXPacira Biosciences, Inc.$1.5B100
PAHCPhibro Animal Health Corp.$1.4B92
ETONEton Pharmaceuticals, Inc.$1.8B99
BCRXBioCryst Pharmaceuticals, Inc.$1.9B82
AMPHAmphastar Pharmaceuticals, Inc.$1.3B94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alvotech — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALVO news & analysis

Alvotech (ALVO) Presents at UBS Global Biopharma Conference 2026 Transcript

Seeking Alpha · 18 Nov 2026neutral

Alvotech founder and executive chairman Robert Wessman and chief strategy officer Balaji Prasad participated in the UBS Global Biopharma Conference 2026. The excerpt provides the conference opening but no further discussion or company updates.

Why it matters — The transcript identifies Alvotech’s participating executives, but the excerpt contains no substantive company information for ALVO watchers to assess.

What Alvotech (ALVO) Said on Its Q3 Earnings Call

MarketBeat · 12 Nov 2026negative

Alvotech said it expects full-year revenue and adjusted earnings near the lower end of its guidance range. The company is working to increase deliveries following a manufacturing slowdown.

Why it matters — ALVO watchers may note the lower-end outlook and the effort to raise deliveries after the slowdown.

Alvotech (ALVO) Reports Q3 Loss, Lags Revenue Estimates

Zacks Investment Research · 11 Nov 2026negative

Alvotech reported a third-quarter loss of $0.03 per share, compared with the Zacks Consensus Estimate of a $0.01 loss. The prior-year quarterly loss was $0.02 per share.

Why it matters — The reported loss was greater than the consensus estimate, a result ALVO watchers may note when reviewing the company’s quarterly performance.

Will Alvotech (ALVO) Report Negative Earnings Next Week? What You Should Know

Zacks Investment Research · 4 Nov 2026negative

Zacks Investment Research says Alvotech lacks the combination of two key ingredients associated with a likely earnings beat in its upcoming report. The headline frames the item around whether the company will report negative earnings next week.

Why it matters — ALVO watchers may find the item relevant as it highlights expectations and uncertainty ahead of the upcoming earnings report.

FAQ

Frequently asked questions about ALVO stock

What is the ALVO stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Alvotech have a median 12-month price target of $8, with estimates ranging from $4 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALVO stock a buy right now?

Of the 7 analysts covering Alvotech, 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alvotech 32 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALVO?

As at 17 Nov 2026, Alvotech ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).

Will ALVO stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +75.8% from the last close, and Ticker Nerd's factor model ranks Alvotech 32 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALVO stock forecast for 2030?

No analyst covering Alvotech publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALVO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $9 over the next 12 months.

How has ALVO stock performed over the past year?

Alvotech returned -11.0% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alvotech do?

Alvotech SA is a biotechnology company focused on the development and manufacture of biosimilar medicines. Alvotech SA specializes in creating high-quality, cost-competitive alternatives to established biologic therapies, with products and candidates spanning autoimmune diseases, eye disorders, osteoporosis, respiratory disease, oncology, and other therapeutic areas.

What is the latest news on ALVO?

The most recent item we track (Seeking Alpha, 18 Nov 2026): "Alvotech (ALVO) Presents at UBS Global Biopharma Conference 2026 Transcript". Alvotech founder and executive chairman Robert Wessman and chief strategy officer Balaji Prasad participated in the UBS Global Biopharma Conference 2026. The excerpt provides the conference opening but no further discussion or company updates.

Company

About Alvotech.

Alvotech SA is a biotechnology company focused on the development and manufacture of biosimilar medicines. Alvotech SA specializes in creating high-quality, cost-competitive alternatives to established biologic therapies, with products and candidates spanning autoimmune diseases, eye disorders, osteoporosis, respiratory disease, oncology, and other therapeutic areas. The company operates a vertically integrated model that covers the biosimilar value chain from cell line development and research to commercial manufacturing. Its portfolio includes monoclonal antibodies and fusion proteins designed to support treatment access across global patient markets. Alvotech SA works through strategic partnerships to extend commercialization and distribution reach across North America, Europe, Asia, and other international markets. Headquartered in Luxembourg, Alvotech SA plays a role in expanding access to biosimilar medicines within the global biopharmaceutical sector.

CEO Mr. Robert Wessman · 1,279 employees · Luxembourg · https://www.alvotech.com